A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity

Tracy E Garrett,Richard A Morgan,Stacie L Seidel,Howard J Latimer,Byoung Y Ryu,John W Evans,Christopher J Horvath,Alena A Chekmasova,Johanna A Griecci,Holly M Horton,Kevin M Friedman

doi:10.1186/2051-1426-3-s2-p124

Tracy E Garrett, Richard A Morgan + Show 9 more

Open Access

https://doi.org/10.1186/2051-1426-3-s2-p124

Copy DOI

Abstract

Meeting abstracts Chimeric antigen receptors (CARs) operably link T cell activation domains to the antigen recognition properties of an antibody, thereby redirecting T lymphocytes to cells expressing the antigen. B cell maturation antigen (BCMA) is an attractive CAR T cell target to treat patients

Highlights

Chimeric antigen receptors (CARs) operably link T cell activation domains to the antigen recognition properties of an antibody, thereby redirecting T lymphocytes to cells expressing the antigen
We tested four candidate anti-B cell maturation antigen (BCMA) CARs each comprised of unique single chain variable fragments from antibodies specific to BCMA fused to CD3zeta and CD137 (4-1BB) signaling domains
Candidate anti-BCMA CARs were introduced into T cells via lentiviral vector technology, and the transduced T cells expanded using a scalable clinical manufacturing process

Summary

Introduction

Chimeric antigen receptors (CARs) operably link T cell activation domains to the antigen recognition properties of an antibody, thereby redirecting T lymphocytes to cells expressing the antigen. A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA.

Results

Conclusion